

# Lead, represent, develop and support Australian critical care nurses

Welcome to the February edition of the ACCCN Newsletter.

The ANZICS/ACCCN Annual Scientific Meeting (ASM), which incorporates the annual Paediatric and Neonatal Intensive Care Conference begins in **less than 2 months** and the Organising Committee looks forward to welcoming all delegates to Sydney.

The theme of the meeting is "Harbouring Excellence in Intensive Care and Beyond" and will focus upon the excellence and innovation achieved in the intensive care sector throughout Australia, New Zealand and the world.

The ASM provides an ideal opportunity to network with professionals, make new contacts and establish important relationships with leading intensive care professionals.

Sydney is a spectacular host city, boasting the iconic harbour and bridge, cultural venues, international cuisine and surf beaches. The ASM will be held at the International Convention Centre Sydney (ICC Sydney) which is conveniently located at Darling Harbour on the harbour foreshore, in the heart of the city centre.

ACCCN Members receive up to \$150 discount off registration fees. Early bird registration closes on 11<sup>th</sup> March so book early and save! **Register Here** 



# **ACCCN Journal Club**

The inaugural ACCCN journal club was conducted on 23rd February at 1800hrs facilitated via zoom by Ms Julia Pilowsky, Dr Rosalind Elliott and Dr Kaye Rolls (NSW Branch).

The focus of the discussion was a paper by Josepha op't Hoog, S. A. J., Eskes, A. M., van Mersbergen-de, M. P. J., Pelgrim, T., van der Hoeven, H., Vermeulen, H., & Vloet, L. C. M. (2021). The effects of intensive care unit-initiated transitional care interventions on elements of post-intensive care syndrome: A systematic review and meta-analysis. *Australian Critical Care*. The publication was critically appraised using the CASP guidelines. The session was well received by the small number of attendees.

The next journal club will be conducted on Wednesday 18th May 1800-1930 hrs. Dr Kaye Rolls will lead the session with guest facilitator Professor Janice Gullick. The paper to be appraised is by Slettmyr, A., Frank, C., & Falk, AC. (2022). The core of patient-participation in the Intensive Care Unit: The patient's views. *Intensive and Critical Care Nursing*, 68, 103119. <u>https://doi.org/10.1016/j.iccn.2021.103119</u>

Attendance is via zoom and free of charge for ACCCN members.

Julia, Roz and Kaye look forward to seeing you online!



### **NSW/ACT Members' Professional Development Fund 2022**

Are you ACCCN member in NSW or ACT? Are you interested in funding assistance to attend the upcoming ANZICS/ACCCN Intensive Care ASM or perhaps another educational activity relevant to critical care?

Click here for more information and to apply

Closing date - Sunday 3 April 2022

### **SA/NT Members' Professional Development Fund 2022**

Are you ACCCN member in SA or NT? Are you interested in funding assistance to attend the upcoming ANZICS/ACCCN Intensive Care ASM or perhaps another educational activity relevant to critical care?

Click here for more information and to apply

Closing date - Sunday 27 March 2022

### Victoria Branch Critical Care Nursing Graduate Prizes 2021

ACCCN Victoria Branch is delighted to announce the prize winners for 2021. These graduate prizes are awarded for demonstrating excellence in critical care nursing in the clinical and academic domains and for displaying a high level of professional behaviour. Each prize winner has been judged as the 'best critical care nursing graduate' at their relevant educational institution. Congratulations....

Alice Batterton – Australian Catholic University Jade McWaters – Deakin University Emily Picken – Latrobe Bundoora Clair Borci – Melbourne University Jessica Bye – Monash University

# Call for Expressions of Interest for ANZICS/ACCCN Intensive Care Annual Scientific Meeting (ASM) 2023

#### Adult and Paediatric Nursing Convenors

ACCCN is seeking Expressions of Interest from members based in South Australia to assist with the 2023 ANZICS/ACCCN ASM. The 2023 ASM is scheduled to be held in Adelaide, South Australia, 28-31 March. Appointments are for a term of one (1) year leading up to the 2023 ASM.

#### Click here for further details

Closing date - 5pm on Wednesday 16 March 2022



ANZICS/ACCCN Intensive Care ASM

#### **Organising Committee**

ANZICS/ACCCN is seeking Expressions of Interest from ANZICS/ACCCN members nationally to be involved in the organisation of the Intensive Care Annual Scientific Meeting (ASM) to be held in Adelaide, South Australia, 28-31 March 2023. Appointments are for a minimum term of one (1) year, with the option to re-elect for a second year.

#### Click here for further details

Closing date – 5pm on Wednesday 16 March 2022

# **UPCOMING EVENTS**

# **SA/NT Hot Topic**



ACCCN

SA/NT 'Virtual' Hot Topic Evening **'Sepsis – How to manage sizzling symptoms in cool ways'** Tuesday 29<sup>h</sup> March 2022 7:00pm – 8:30pm Via zoom



# ACCCN Journal Club



ACCCN Online Journal Club Wednesday 18<sup>th</sup> May 2022 6:00pm – 7:30pm Via zoom, facilitated by NSW Branch

'The core of patient-participation in the Intensive Care Unit: The patient's views'



### **VIC Critical Care Seminar**



Postponed from October 2021

In Case U missed it: Innovations and Inspiration

A ACCCN

ACCCN

in O

VIC Critical Care Seminar Friday 3 June, 2022 Oaks on Market, Melbourne



### **Tassie Trauma Day**







# **FEBRUARY 2022**

COVID-19 CLINICAL EVIDENCE TASKEORCE

# COMMUNIQUE



### New recommendations for remdesivir in adults with mild COVID-19

The Taskforce Disease-Modifying Treatment and Chemoprophylaxis Panel have reviewed the results from the <u>PINETREE</u> trial (27/1/22) and determined that remdesivir probably reduces the incidence of hospitalisation in adults with mild COVID-19 who have one or more risk factors for disease progression.

As a result, the Taskforce has made two recommendations for its use:

### Conditional recommendation

Consider using remdesivir within 7 days of symptom onset in unvaccinated\* adults with COVID-19 who do not require oxygen and who have one or more risk factors for disease progression.

Within the patient population for which remdesivir is conditionally recommended for use (see remark), decisions about the appropriateness of treatment with remdesivir should be based on the patient's individual risk of severe disease, on the basis of age and multiple risk factors, COVID-19 vaccination status and time since vaccination.

### Consensus recommendation

In addition to at-risk unvaccinated adults, also consider using remdesivir within 7 days of symptom onset in adults with COVID-19 who do not require oxygen and:

are immunocompromised regardless of vaccination status; or

have received one or two doses of vaccine and who are at high risk of severe disease on the basis of age and multiple risk factors.

The remark accompanying the recommendation defines immunocompromising conditions.

Remdesivir is now being considered by our special population panels to determine whether additional recommendations are needed for these groups.

### Paediatric panel reviews Lagevrio and Paxlovid

Following the recent publication of Taskforce recommendations on the use of molnupiravir (Lagevrio) and nirmatrelvir plus ritonavir (Paxlovid) in adults, the Taskforce Paediatric and Adolescent Care Panel have reviewed the evidence in the context of this population and made two new recommendations:

### Molnupiravir (Lagverio)

### **Conditional recommendation against**

Do not routinely use molnupiravir for the treatment of COVID-19 in children and adolescents. Until further evidence is available and given the potential for harmful effects, molnupiravir should not be considered routinely in this population. If treatment is considered—in exceptional circumstances—it should be in consultation with a clinical reference group, such as the <u>ANZPID COVID-19 Clinical</u> <u>Reference Group</u>. Informed consent from parents/caregivers should also be obtained. Currently, there is no direct evidence for the use of molnupiravir in children or adolescents.

### Nirmatrelvir plus ritonavir (Paxlovid)

### Only in research settings

Do not use nirmatrelvir plus ritonavir in children and adolescents outside of randomised trials with appropriate ethical approval.

Trials are needed in special populations, including children and adolescents. Until further evidence is available, do not use nirmatrelvir plus ritonavir (Paxlovid) for the treatment of COVID-19 in children and adolescents unless they are eligible to be enrolled in trials.

Currently nirmatrelvir plus ritonavir is not approved for use in people under 18 years of age.

# **Employment Opportunities**



### **Registered Nurse - Intensive Care Unit**

Permanent full time and part-time opportunities for Critical Care Registered Nurses with postgraduate qualifications.

Intensive Care Units at Monash Medical Centre are looking to grow the dedicated & skilled teams to support the growth within the service, and we are wanting you to bring your demonstrated knowledge and experience within Critical Care, to look after our patients.

We are seeking candidates with demonstrated Critical Care experience with a Post Grad in Critical Care. Your demonstrated experience within an ICU environment will see you flourish in our critical care environments.

As someone with a strong work ethic, self-motivation and personal values your contribution with the team will support each other and our organisation to be leaders in our field with exciting and progressive treatment and care.

You are adaptable to a changing environment as we work together to deliver first class service. Alongside your caring and engaging manner, you have a positive work attitude, strong communication skills and a strong people-person focus allowing you to engage with our patients and their families.

Flexibility to work a minimum of 24 hours per week across a 24/7 rotating roster

Monash Health recognises the value of equal employment opportunity and is committed to patient safety and promoting fairness, equity and diversity in the workplace. At Monash Health we are relentless in our pursuit of excellence and work to our six guiding principles.

#### How to Apply

Applications will only be accepted via the Monash Health online Mercury System only. Email applications will not be considered.

Existing Monash Health Employees should apply using your Monash Health employee account. For any queries regarding employee accounts contact Recruitment Services by email – recruitment@monashhealth.org.

Apply NOW to be part of our Critical Care Program at Monash Health

For more details about the role plus how to apply, please refer to attached 'Application Guide' located under Position Documents.

To view the full position description and to apply now, click here